Skip to main content

Collegium Pharmaceutical, Inc.

corporate_fare Company Profile

Collegium Pharmaceutical, Inc.

COLL·NASDAQ·Life Sciences·CIK 0001267565

The company is a diversified biopharmaceutical company focused on improving the lives of people with serious medical conditions. It develops, licenses, and acquires differentiated products for attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. The company commercializes its products in the United States. Key products include Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively "Nucynta Products"), and Symproic. Jornay PM is a central nervous system (CNS) stimulant prescription medicine containing methylphenidate HCl, a Schedule II methylphenidate. It was approved by the U.S. Food and Drug Administration (FDA) in August 2018 for treating ADHD in people six years of age and older. Jornay PM is currently the only FDA-approved stimulant medication dosed in the evening. The company acquired Ironshore, which developed Jornay PM, on September 3, 2024, expanding its business into neuropsychiatry via the ADHD market. Belbuca is a buccal film containing buprenorphine, a Schedule III opioid. It was FDA-approved in October 2015 for severe and persistent pain requiring extended daily opioid analgesic treatment when other options are inadequate. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone, a Schedule II opioid. It uses the DETERx technology platform, which combines an active opioid ingredient with a fatty acid and waxes to form microspheres in a capsule. These wax-based microspheres are designed to resist particle size reduction and dose dumping when physically and chemically manipulated, aiming to deter abuse and misuse like crushing, chewing, heating, and injecting.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for COLL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for COLL spans 10-Q, 8-K, 8-K/A, 10-K.

Recent high-impact activity:

  • Collegium 10-Q: Q3 Net Income $21.8M, EPS $0.60, $1.1B Debt Load Detailed
  • Collegium Q3'26: Record $216.3M Revenue, EPS $0.60, 2026 Guidance Reaffirmed
  • Collegium Posts 3Q EPS of 60 Cents
  • Collegium Pays $17M to End Nucynta Patent Fight With Grünenthal
  • Collegium Pays $17M to Settle Nucynta Patent Suit and End Grünenthal Royalties

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$780.57M
Net Income
$62.87M
Diluted EPS
$1.73
Op. Cash Flow
$329.32M
Free Cash Flow
$327.58M
Gross Profit
$463.26M
Operating Income
$179.64M
Cash & Equivalents
$231.25M
Debt / Equity
0.00×
Net Margin
8.1%
Shares Outstanding
31.71M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-011992

Short Interest & Short Volume

9.40 days to cover

FINRA reported short interest of 5,194,875 shares in COLL as of the October 30, 2026 settlement, a 3.4% decrease from the prior period — about 9.4 days to cover at its recent average daily volume. On November 20, 2026, 51.0% of COLL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,194,875 shares as of October 30, 2026
Change vs prior period▼ 3.4%
Days to cover9.40 at avg daily volume of 552,891
Daily short volume (FINRA facilities)51.0% of 155,184 shares on November 20, 2026
5-day average short volume52.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$24.72
52-week range · as of 2026-11-05 $21.43 – $50.79
Market cap
$768.18M
Volume
528K (0.8× avg)
3-mo avg 630.7K
Live data · 2026-11-21 22:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed COLL - Latest Insights

COLL
Nov 05, 2026, 7:34 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.97
Real-time Price: $24.72 info
Change: +$0.750 (+3%) info
Market Cap: $768.184M info
COLL
Nov 05, 2026, 7:32 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.97
Real-time Price: $24.72 info
Change: +$0.750 (+3%) info
Market Cap: $768.184M info
COLL
Nov 05, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $23.97
Real-time Price: $24.72 info
Change: +$0.750 (+3%) info
Market Cap: $768.184M info
COLL
Oct 19, 2026, 4:13 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $23.01
Real-time Price: $24.72 info
Change: +$1.71 (+7%) info
Market Cap: $768.184M info
COLL
Oct 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.01
Real-time Price: $24.72 info
Change: +$1.71 (+7%) info
Market Cap: $768.184M info
COLL
Aug 13, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.39
Real-time Price: $24.72 info
Change: -$1.67 (-6%) info
Market Cap: $768.184M info
COLL
Aug 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $26.06
Real-time Price: $24.72 info
Change: -$1.34 (-5%) info
Market Cap: $768.184M info
COLL
Aug 06, 2026, 7:34 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.85
Real-time Price: $24.72 info
Change: -$7.13 (-22%) info
Market Cap: $768.184M info
COLL
Aug 06, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.85
Real-time Price: $24.72 info
Change: -$7.13 (-22%) info
Market Cap: $768.184M info
COLL
Aug 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.00
Real-time Price: $24.72 info
Change: -$8.28 (-25%) info
Market Cap: $768.184M info
COLL
Jun 30, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $36.20
Real-time Price: $24.72 info
Change: -$11.48 (-32%) info
Market Cap: $768.184M info
COLL
May 12, 2026, 7:43 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $35.94
Real-time Price: $24.72 info
Change: -$11.22 (-31%) info
Market Cap: $768.184M info
COLL
May 12, 2026, 7:31 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $35.94
Real-time Price: $24.72 info
Change: -$11.22 (-31%) info
Market Cap: $768.184M info
COLL
May 07, 2026, 7:39 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $38.00
Real-time Price: $24.72 info
Change: -$13.28 (-35%) info
Market Cap: $768.184M info
COLL
May 07, 2026, 7:34 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $38.00
Real-time Price: $24.72 info
Change: -$13.28 (-35%) info
Market Cap: $768.184M info
COLL
May 07, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.00
Real-time Price: $24.72 info
Change: -$13.28 (-35%) info
Market Cap: $768.184M info
COLL
Mar 19, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $36.30
Real-time Price: $24.72 info
Change: -$11.58 (-32%) info
Market Cap: $768.184M info
COLL
Mar 19, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $34.80
Real-time Price: $24.72 info
Change: -$10.08 (-29%) info
Market Cap: $768.184M info
COLL
Feb 26, 2026, 7:34 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $44.45
Real-time Price: $24.72 info
Change: -$19.73 (-44%) info
Market Cap: $768.184M info
COLL
Feb 26, 2026, 7:32 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $44.45
Real-time Price: $24.72 info
Change: -$19.73 (-44%) info
Market Cap: $768.184M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets